Patients in a test tube: Horizon Discovery's IP strategy

30-04-2014

Patients in a test tube: Horizon Discovery's IP strategy

Horizon Discovery’s cell line-creating technology has the potential to advance personalised medicine. But how does the gene editing company stay competitive in a crowded field? LSIPR found out.

Editing the genome

As a better understanding of how genes function in disease is developing, personalised medicine is becoming a reality for more patients.

Since the 1990s, advances in technology have allowed the manipulation, or ‘editing’, of the human genome so that the function of certain genes and how genetic mutations cause the onset of disease can be studied.


Horizon Discovery, IP strategy, personalised medicine, gene editing, cell lines

LSIPR